Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension

Hypertension

Volumn 29, Issue 1 II, 1997, Pages 177-187

  Phillips, M Ian ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

adeno associated viral vector; angiotensin; antisense oligonucleotide; AT1 receptor

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; ANTISENSE OLIGODEOXYNUCLEOTIDE; LIPOSOME; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ARTICLE; GENE THERAPY; GENETIC TRANSFECTION; HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0031017162     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.29.1.177     Document Type: Article

References (74)

1. Whelton PK. Epidemiology of hypertension. Lancet. 1994;334: 101-106.
2. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic and cardiovascular risks: US population data. Arch Intern Med. 1993;153:598-615.
3. Burt VL, Whelton PK, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarth D. Prevalence of hypertension in the US adult population: results from the 3rd National Health and Nutrition Examination Survey, 1988-1991 .Hypertension. 1995;25:305-313.
4. Lifton RP. Molecular genetics of human blood pressure variation. Science. 1996;272:676-680.
5. Junemaitre X, Soubrier F, Kotelvtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, William RR, Lalouel JM, Corvol P. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169-180.
6. Tanimoto K, Sugiyama F, Goto Y, Ishida J, Takimoto E, Yagami K, Fukamizu A, Murakami K. Angiotensinogen-deficient mice with hypotension. J Biol Chem. 1994;269:31334-31337.
7. Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, Jenneue JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA. 1995;92:2735-2739.
8. Schinke M, Bohm M, Bricca G, Ganten D, Bader M. Permanent inhibition of angiotensinogen synthesis of antisense RNA expression. Hypertension. 1996;27:508-513.
9. Phillips MI, Kimura B. Brain angiotensin in the developing spontaneously hypertensive rat. J Hypertens. 1988;6:607-612.
10. Nazarali AJ, Gutkind JS, Correa FM, Saavedra JM. Decreased angiotensin II receptors in subfornical organ of spontaneously hypertensive rats after chronic antihypertensive treatment with enalapril. Am J Hypertens. 1990;3:59-61.
11. Phillips MI, Mann JFE, Haebara H, Hoffman WE, Dietz R, Schelling P, Ganten D. Lowering of hypertension by central saralasin in the absence of plasma renin. Nature. 1977;270:445-447.
12. Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. Nature. 1994;372:333-335.
13. Crooke ST. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol. 1992;32:329-376.
14. Stein CA, Cheng Y-C. Antisense oligonucleotides: is the bullet really magical? Science. 1993;261:1004-1012.
15. Chiasson BJ, Hooper ML, Murphy PR, Robertson HA. Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain. Eur J Pharmacol. 1992;277:451-453.
16. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science. 1993;259:528-531.
17. Wahlestedt C, Golanov E, Yamamoto S, Yee F, Ericson H, Yoo H, Inturrisi CE, Reis DJ. Antisense oligonucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischemic infarctions. Nature. 1993;363:260-263.
18. McCarthy MM, Masters DB, Rimvall K, Schwartz-Giblin S, Pfaff DW. Intracerebral administration of antisense oligodeoxynucleotides to GAD65 and GAD67 mRNAs modulates reproductive behavior in the female rat. Brain Res. 1994;636:209-220.
19. 1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul Pep. 1993;49:167-174.
20. Simons RW. Naturally occurring antisense RNA control: a brief review. Gene. 1988;72:35-44.
21. Stull RA, Taylor LA, Szoka FC. Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices. Nucl Acids Res. 1992;20:3501-3508.
22. Cowsert LM, Fox MC, Zon G, Mirabelli CK. In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of Papillomavirus: potential treatment for genital warts. Antimicrob Agents Chemother. 1993;37:171-177.
23. Wakita T, Wands JR. Specific inhibition of hepatitis C virus expression by antisense oligonucleotides: in vitro model for selection of target sequence. J Biol Chem. 1994;269:14205-14210.
24. Lima WF, Monia BP, Ecker DJ, Freier SM. Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry. 1992;31:12055-12061.
25. Rittner K, Sczakiel G. Identification and analysis of antisense RNA target regions of the human immunodeficiency virus type 1. Nucl Acid Res. 1991;19:1421-1426.
26. Jaroszevski JW, Syi JL, Ghosh M, Ghosh K, Cohen JS. Targeting of antisense DNA: comparison of activity of anti-rabbit beta-globin oligodeoxyribonucleoside phosphorothioates with computer predictions of mRNA folding. Antisense Res Dev. 1993;3:339-348.
27. Burgess T, Farrell C. The antiproliferative activity of c-myb and ac-myb antisense oligonucleotides in smooth muscle cells is caused by a non-antisense mechanism. Proc Natl Acad Sci U S A. 1995;92: 4051-4055.
28. Singer M, Berg P. In: Genes and Genomes. Mill Valley, Calif: University Science Books; 1992:54-59.
29. Iversen PL, Zhu S, Meyer A, Zon G. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev. 1992;2:211-222.
30. Colige A, Sokolov BP, Nugent P, Baserge R, Prockop DJ. Use of an antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cells. Biochemistry. 1993;32:7-11.
31. Helene C. The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides. Anticancer Drug Res 1991;6: 569-584.
32. Bennett CF, Condon TP, Grimm S, Chan H, Chiang MY. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol. 1994;152:3530-3540.
33. Bacon TA, Wickstrom E. Walking along human c-myc mRNA with antisense oligonucleotides: maximum efficacy at the 5′ cap region. Oncogene Res. 1991;6:13-19.
34. Wahlestedt C. Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol Sci. 1994;15:42-46.
35. Li B, Hughes JA, Phillips MI. Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells. Neurochem Int. In press.
36. Campbell JM, Bacon TA, Wickstrom E. Oligodeoxynucleotide phosphorothioate stability in subcellular extracts, culture media, ser and cerebrospinal fluid. J Biochem Biophys Methods. 1990;20:259-267.
37. Takaku H. Properties and anti-HIV activity of nicked dumbbell oligonucleotides. Neurotide. 1996;15:519-529.
38. Stein CA. Exploiting the potential of antisense: beyond phosphorothioate oligodeoxynucleotides. Chem Biol. 1996;3:319-323.
39. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci U S A. 1989;86:3474-3478.
40. Wagner RW, Mattenci MD, Lewis JG, Gutierrez AJ, Moulds C, Froehler BC. Antisense gene inhibition by oligonucleotides containing C-5 mopyne primidines. Science. 1993;260:1510-1513.
41. Iversen PL, Mata J, Tracewell WG, Zon G. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1I in the adult male rat following single injections and continuous infusion. Antisense Res Dev. 1994; 4:43-52.
42. Phillips MI, Wielbo D, Gyurko R. Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes. Kidney Int. 1994;46:1554-1556.
43. Wielbo D, Simon A, Phillips MI, Toffolo S. Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. Hypertension. 1996;28:147-151.
44. Tomita N, Morishita R, Higaki J, Kaneda Y, Mikami H, Ogihara T. In vivo transfer of antisense oligonucleotide against rat angiotensinogen with HJV-liposome delivery resulted in reduction of blood pressure in SHR. Hypertension. 1994;24:397.
45. Suzuki S, Pilowsky P, Minson J, Amolda L, Llewellyn-Smith I, Chalmers J. c-fos antisense in rostral ventral medulla reduces arterial blood pressure. Am J Physiol. 1994;35:R1418-R1422.
46. Suzuki S, Pilowsky P, Minson J, Amolda L, Llewellyn-Smith I, Chalmers J. Antisense to thyrotropin releasing hormone receptor reduces arterial blood pressure in spontaneously hypertensive rats. Clin Res. 1995;77:679-683.
47. 1A receptor. Regul Pep. 1995;59:171-182.
48. Wielbo D, Sernia C, Gyurko R, Phillips MI. Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension. 1995;25:314-319.
49. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA co-introduced with nuclear protein in adult rat liver. Science. 1989;243: 375-378.
50. Galli SM, Varela A, Phillips MI. Lowering of blood pressure and catecholamines in chronic but not in acute 2 kidney-1 clip rats by antisense oligonucleotide to angiotensin mRNA. Hypertension. 1995; 26:557. Abstract.
51. Simons M, Edelman ER, DeKeyser J-L, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature. 1992;359:67-70.
52. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ, Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene. 1994;149:13-19.
53. Bennett MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest. 1994;93:820-828.
54. Wang C, Chao L, Chao J. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest. 1995;95:1710-1716.
55. Lin K-F, Chao J, Chao L. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension. 1995;26:847-853.
56. 1 receptors and angiotensin II action in astroglial and neuronal cells in primary cultures from the brain. Proc Natl Acad Sci U S A. 1995; 92:1162-1166.
57. 1 receptor. Exp Biol. 1996;9:1558. Abstract.
58. Willard JE, Jesse ME, Gerard RD, Meidell RS. Recombinant adenovirus is an efficient vector for in vivo gene transfer and can be preferentially directed at vascular endothelium or smooth muscle cells. Circulation. 1992;86:473.
59. Wu P, Du B, Phillips MI, Terwilliger EF. Efficient and long-term gene delivery into rat brain using adeno-associated viral vectors. Soc Neuroscience. 1996;22:133.2. Abstract.
60. Zolothukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N. A 'humanized' green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol. 1996;70:4646-4654.
61. Mulligan RC. The basic science of gene therapy. Science. 1993; 260:926-932.
62. Brody SL, Jaffe HA, Eissa NT, Daniel C. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet. 1994;8:42-51.
63. Quantin B, Perricaudet LD, Tajbakhsh S, Mandel J-L. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci USA. 1992;89:2581-2584.
64. Le Gal La Salle G, Robert JJ, Berrard S, Ridoux V, Stratford-Perricaudet LD, Perricaudet M, Mallet J. An adenovirus vector for gene transfer into the neurons and glia in the brain. Science. 1993;259: 988-990.
65. Muzyczka N, McLaughlin S. Use of adeno-associated virus as a mammalian transduction vector. In: Gluzman Y, Hughes SH, eds. Current Communications in Molecular Biology: Viral Vectors. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press: 1988:39-44.
66. Ponnazhagan S, Nallari ML, Srivastava A. Suppression of human a-globin gene expression mediated by the recombinant adeno-associ-ated virus 2-based antisense vectors. J Exp Med. 1994;179:733-738.
67. Chatterjee S, Johnson PR, Wong KK. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science. 1992;258:1485-1488.
68. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. In: Current Topics in Microbiology and Immunology: Berlin, Germany: Springer-Verlag; 1992;158:97-129.
69. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, Hunter LA. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 1991;10:3941-3950.
70. Linden RM, Winocour E, Berns KI. The recombination signals for adeno-associated virus site-specific integration. Proc Natl Acad Sci U S A. 1996;93:7966-7972.
71. Lebkowski JS, McNally MM, Okarma TB, Lerch B. Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types. Mol Cell Biol. 1988; 8:3988-3996.
72. Flotte TR, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, Taylor G, Walden S, Wetzel R. A phase I study of an adeno-associated virus-CTFR gene vector in adult CF patients with mild lung disease. Hum Gene Ther. 1996;7:1145-1159.
73. Gyurko R, Phillips MI. Antisense expression vector decreases angiotensin receptor binding in NG108-15 cells. Exp Biol. 1995;9:1915. Abstract.
74. 1-R mRNA antisense. Hypertension. 1997;28(part 2):374-380.